Comparing the FIT with a noninvasive, mts-DNA test that includes quantitative molecular assays for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, aberrant N-Myc downstream-regulated gene 4 (NDRG4), bone morphogenetic protein 3 (BMP3) methylation, and β-actin, plus Hb immunoassays, the mts-DNA test detected more cancers than the FIT, but it has shown a significant number of false positive results. Here, KRAS is linked to cancer.